Beyond Animal Models: VivoSim's China Entry Redefines Drug Safety

SAN DIEGO, CA – July 21, 2026 – A press release from San Diego-based VivoSim Labs this week announced its first commercial sales in China. On the surface, it’s a standard story of a U.S. biotech services company expanding its global footprint. But beyond the launch, this move signifies something far more profound: a critical beachhead in a global revolution that aims to overhaul how we ensure new medicines are safe and effective, long before they reach a single patient.

VivoSim, a provider of what are called New Approach Methodologies (NAMs), has secured its first paid programs on the Chinese mainland with two significant players: a leading oncology biotech in the innovation hub of Shanghai and a large pharmaceutical company in Chengdu. The deal brings VivoSim’s advanced testing platform—which uses 3D human organ models combined with artificial intelligence—into the world’s second-largest and fastest-growing pharmaceutical market. This isn’t just a new market entry; it's a validation of a future where drug development is faster, cheaper, and, most importantly, more predictive of human outcomes by moving beyond traditional animal testing.

The China Beachhead: Tapping a Pharmaceutical Superpower

For VivoSim, the timing could not be better. China is no longer just a manufacturing hub but a formidable engine of drug innovation. The country’s drug regulator, the National Medical Products Administration (NMPA), approved a record 76 innovative drugs in 2025, a dramatic increase from 48 the previous year. This acceleration is fueled by sweeping regulatory reforms, including a 30-working-day fast-track review channel for innovative drug applications, designed to attract and foster cutting-edge R&D.

“China is now the world’s second-largest pharmaceutical market and among the fastest-moving sources of drug innovation globally,” said Tony Lialin, Chief Commercial Officer of VivoSim, in the company’s announcement. He noted the sales show “real, paying demand for the human-relevant safety and efficacy data VivoSim is built to deliver.”

VivoSim’s internal analysis sizes its addressable market in China for liver and gastrointestinal models at approximately $2 billion, a figure supported by external analysis of China's preclinical services sector, which shows a projected compound annual growth rate of over 10%. By securing initial contracts through its local distributor, Tekon, VivoSim has not only validated its channel strategy but also gained a crucial foothold. Partnering with a leading oncology firm in Shanghai places it at the heart of China’s most vibrant biotech ecosystem, while the engagement with a large Chengdu-based pharmaceutical demonstrates its appeal to established players, expanding its reach beyond the coastal innovation corridors.

The Science of Safety: Beyond Animal Testing

The strategic business move is underpinned by a powerful scientific one. For decades, the pharmaceutical industry has relied on animal models to test for drug toxicity. Yet, this has always been an imperfect system. The physiological differences between a mouse or a rat and a human are vast, leading to poor translation of results. The industry-accepted sensitivity of animal models for predicting liver toxicity, for example, hovers between 50% and 65%. This gap means potentially harmful compounds can advance to human trials, while potentially life-saving ones are discarded unnecessarily.

VivoSim’s NAMkind™ platform offers a compelling alternative. The company builds miniature, functional 3D models of human livers and gastrointestinal tracts using primary cells from human donors. These “organoids” are then used to test how a drug candidate behaves in a system that is biologically human. The platform’s proprietary AI, trained on an extensive real-world dataset, analyzes the results to identify safety liabilities and measure a drug’s intended biological effect.

The results are striking. In a benchmarking study against 92 compounds with known clinical outcomes, VivoSim’s liver model achieved 91% predictive accuracy, with 90% sensitivity and 95% specificity. This leap in predictive power is what gives development teams the confidence to make critical “go/no-go” decisions earlier and with greater certainty.

“The science behind these wins is what makes them repeatable,” said Amar Sethi, MD, PhD, VivoSim’s Chief Scientific Officer. “Our multi-endpoint profiling gives development teams in China the same translational signatures we deliver to partners in the U.S. and Europe — the ability to move from detecting liabilities to predicting risk, long before a single patient is dosed.”

A Global Regulatory Tailwind

VivoSim's expansion into China is happening amidst a powerful global shift in regulatory thinking. In the United States, the FDA Modernization Act 2.0, signed into law in late 2022, officially removed the decades-old mandate requiring animal testing for new drugs, explicitly allowing sponsors to use alternative methods like organ-on-a-chip technology and computer modeling. The FDA’s April 2025 plan to phase out animal testing for certain drugs, mentioned by VivoSim, is a direct follow-through on this legislative sea change, signaling to the industry that human-relevant data is not just welcome, but preferred.

This momentum is mirrored in Europe, where the European Medicines Agency (EMA) actively encourages the adoption of NAMs. Now, China’s NMPA is showing signs of following suit. While primarily seen in the cosmetics sector, where China has been progressively eliminating mandatory animal testing to align with international standards, the underlying principle is clear: a move toward scientifically robust, non-animal evidence. For a country eager to establish itself as a global leader in drug innovation, adopting the most advanced and predictive testing methodologies is a logical and necessary step.

This converging regulatory landscape creates a durable tailwind for companies like VivoSim. As drug sponsors in China increasingly seek to develop drugs for global markets, using testing methods accepted by the FDA and EMA becomes a strategic advantage.

The Human and Financial Impact

The implications of this technological shift extend far beyond corporate revenues and regulatory filings. The cost of bringing a new drug to market is staggering, in large part because of high failure rates in late-stage clinical trials. A single failure can cost a sponsor between $50 million and $200 million and years of lost time. By providing a more accurate filter at the preclinical stage, VivoSim's technology helps de-risk this massive investment, allowing resources to be focused on candidates with the highest probability of success.

Ultimately, the greatest impact is on human health. Better preclinical models mean that drugs entering clinical trials are more likely to be safe for volunteers and effective for patients. It reduces the risk of unforeseen toxicity events and increases the chance that transformative therapies for diseases like cancer, which the Shanghai client is targeting, will make it to the people who need them. VivoSim's entry into China is more than just a new line on a balance sheet; it is the scaling of a technology that promises a future of smarter, safer, and more humane medicine.